Feng Luo

2.6k total citations
58 papers, 1.8k citations indexed

About

Feng Luo is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Feng Luo has authored 58 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 13 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Feng Luo's work include Functional Brain Connectivity Studies (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Advanced Neuroimaging Techniques and Applications (9 papers). Feng Luo is often cited by papers focused on Functional Brain Connectivity Studies (11 papers), Lung Cancer Treatments and Mutations (10 papers) and Advanced Neuroimaging Techniques and Applications (9 papers). Feng Luo collaborates with scholars based in United States, China and Spain. Feng Luo's co-authors include Gerard B. Fox, Mark L. Day, Shi‐Jiang Li, Gaohong Wu, Jean‐Charles Soria, Rastislav Bahleda, Josep Tabernero, Suso Platero, Bob Zhong and Jeffrey R. Infante and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Feng Luo

58 papers receiving 1.8k citations

Peers

Feng Luo

RNMI

ONCOL

CMN

Roberto Piñeiro Spain

Randolph M. Johnson United States

Hans Wester Germany

Nobusada Shinoura Japan

Andreas Wunder Germany

Jan Dörr Germany

Santiago Rojas Spain

Sébastien Serres United Kingdom

Jerzy Hildebrand Belgium

Haruo Iguchi Japan

Roberto Piñeiro Spain

Feng Luo

616 ×0.9

174 ×0.5

RNMI

508 ×1.6

ONCOL

196 ×0.6

100 ×0.4

CMN

Citations per year, relative to Feng Luo Feng Luo (= 1×) peers Roberto Piñeiro

Countries citing papers authored by Feng Luo

Since Specialization

Citations

This map shows the geographic impact of Feng Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Luo more than expected).

Fields of papers citing papers by Feng Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Luo. The network helps show where Feng Luo may publish in the future.

Co-authorship network of co-authors of Feng Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Feng Luo. A scholar is included among the top collaborators of Feng Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng Luo. Feng Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Ying, Lin Wu, Yong Fang, et al.. (2024). Abstract CT248: Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2 mutant non-small cell lung cancer (NSCLC): primary analysis from the Phase 2 DESTINY-Lung05 (DL-05) trial. Cancer Research. 84(7_Supplement). CT248–CT248. 5 indexed citations

Wang, Li, Li Tu, Yong Zhang, et al.. (2024). Folic Acid-Modified Milk Exosomes Delivering c-Kit siRNA Overcome EGFR-TKIs Resistance in Lung Cancer by Suppressing mTOR Signaling and Stemness. International Journal of Biological Sciences. 21(1). 382–399. 3 indexed citations

Dai, Shuang, Xiaoqin Liu, Qiang Wu, et al.. (2022). A novel SETD3-ALK fusion in lung adenocarcinoma and sustained clinical response to crizotinib. Lung Cancer. 175. 121–124. 1 indexed citations

Zhang, Yichen, Zhihong Chen, Xu‐Chao Zhang, et al.. (2019). Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine. 43. 180–187. 35 indexed citations

Karkera, Jayaprakash D., Dana Gaffney, Ademi Santiago-Walker, et al.. (2017). Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular Cancer Therapeutics. 16(8). 1717–1726. 43 indexed citations

Soria, Jean‐Charles, Antoîne Italiano, Andrés Cervantes, et al.. (2016). Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma. Annals of Oncology. 27. vi269–vi269. 13 indexed citations

Luo, Feng, et al.. (2016). Oridonin inhibition and miR-200b-3p/ZEB1 axis in human pancreatic cancer. International Journal of Oncology. 50(1). 111–120. 30 indexed citations

Wu, Lu, Yanyang Liu, Zhixi Li, et al.. (2014). Anti-tumor Effects of Penfluridol through Dysregulation of Cholesterol Homeostasis. Asian Pacific Journal of Cancer Prevention. 15(1). 489–494. 35 indexed citations

Risinger, Robert, Zubin Bhagwagar, Feng Luo, et al.. (2013). Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. Psychopharmacology. 231(11). 2299–2310. 13 indexed citations

10.

Upadhyay, Jaymin, Scott Baker, Prasant Chandran, et al.. (2011). Default-Mode-Like Network Activation in Awake Rodents. PLoS ONE. 6(11). e27839–e27839. 74 indexed citations

11.

Shineman, Diana W., Guriqbal S. Basi, Jennifer L. Bizon, et al.. (2011). Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimer s Research & Therapy. 3(5). 28–28. 104 indexed citations

12.

Wang, Bilan, Maling Gou, XiuLing Zheng, et al.. (2010). Co-Delivery Honokiol and Doxorubicin in MPEG-PLA Nanoparticles. Journal of Nanoscience and Nanotechnology. 10(7). 4166–4172. 13 indexed citations

13.

Johnson, Faye M., Shruti Agrawal, Howard A. Burris, et al.. (2010). Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumors. Cancer. 116(6). 1582–1591. 104 indexed citations

14.

Wang, Xi-De, Karen A. Reeves, Feng Luo, et al.. (2007). Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome biology. 8(11). R255–R255. 73 indexed citations

15.

Schmidt, Karl, Marcelo Febo, Qiang Shen, et al.. (2006). Hemodynamic and metabolic changes induced by cocaine in anesthetized rat observed with multimodal functional MRI. Psychopharmacology. 185(4). 479–486. 42 indexed citations

16.

Luo, Feng, Zheng‐Xiong Xi, Gaohong Wu, et al.. (2004). Attenuation of brain response to heroin correlates with the reinstatement of heroin-seeking in rats by fMRI. NeuroImage. 22(3). 1328–1335. 30 indexed citations

17.

Lu, Hanbing, Sachin Patel, Feng Luo, et al.. (2004). Spatial correlations of laminar BOLD and CBV responses to rat whisker stimulation with neuronal activity localized by Fos expression. Magnetic Resonance in Medicine. 52(5). 1060–1068. 105 indexed citations

18.

Büchert, Martin, Mark W. Greenlee, Roland M. Rutschmann, et al.. (2002). Functional magnetic resonance imaging evidence for binocular interactions in human visual cortex. Experimental Brain Research. 145(3). 334–339. 21 indexed citations

19.

Li, Zhu, Gaohong Wu, Xiaoli Zhao, Feng Luo, & Shi‐Jiang Li. (2002). Multiecho segmented EPI with z‐shimmed background gradient compensation (MESBAC) pulse sequence for fMRI. Magnetic Resonance in Medicine. 48(2). 312–321. 24 indexed citations

20.

Zheng, Wenxin, Feng Luo, Jean Lu, et al.. (2000). Reduction of BRCA1 Expression in Sporadic Ovarian Cancer. Gynecologic Oncology. 76(3). 294–300. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact